Impact of Allergen-Specific Subcutaneous Immunotherapy on 12-Month Health-Related Quality of Life in Children and Their Parental Caregivers.
Wenjing Zhou, Xingyu Guo, Bo Ding...
https://pubmed.ncbi.nlm.nih.gov/42547470/Actively Recruiting
Led by Wenjing Zhou · Updated on 2024-08-02
600
Participants Needed
1
Research Sites
101 weeks
Total Duration
This research aims to understand how airway allergic diseases like bronchial asthma and allergic rhinitis affect the health-related quality of life HRQoL of children aged 5 to 16 and their parents. It compares children receiving specific immunotherapy with those receiving routine treatment, as well as a healthy control group, to explore the impact on both children and caregiver burden over time. The study uses validated questionnaires and clinical data to assess changes in quality of life and disease severity. Children in the study are divided into groups receiving either subcutaneous allergen-specific immunotherapy or standard treatments such as inhaled corticosteroids and antihistamines. Healthy children without allergic diseases serve as a control group. Data collection includes baseline and follow-up surveys at 1 and 2 years to evaluate quality of life using tools like EQ-5D-Y and disease-specific questionnaires. Clinical assessments include lung function tests, blood tests, and allergy markers. Participants and their parents complete questionnaires at the start and during follow-ups to measure quality of life and caregiver impact. Researchers collect medical records for clinical data and use statistical methods to compare outcomes between treatment groups and healthy controls. The study monitors disease severity and treatment effects over 2 years, aiming to validate new measurement tools and better understand the burden of pediatric allergic diseases on families.
CONDITIONS
The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life
W
Wenjing Zhou
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Wenjing Zhou
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 week before treatment
Participants with allergic diseases complete baseline surveys and clinical data collection before starting their assigned treatment or routine care. Healthy controls complete a single baseline survey.
1 baseline visit (in-person)
Duration - 2 years
Participants undergo routine treatment or specific immunotherapy while completing follow-up surveys and clinical assessments to monitor health-related quality of life and disease severity over time.
2 follow-up visits, annually
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Wenjing Zhou, Xingyu Guo, Bo Ding...
https://pubmed.ncbi.nlm.nih.gov/42547470/Wenjing Zhou
Lead Sponsor